11/24/20 5:30 AMNasdaq : ARDSAridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, is pleased to announce a 75 minute "Fireside Chat Forum," withRHEA-AIneutral
11/20/20 4:05 PMNasdaq : ARDSAridis Pharmaceuticals Announces Third Quarter 2020 ResultsAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the thirdRHEA-AIneutral
10/27/20 4:24 PMNasdaq : ARDS/C O R R E C T I O N -- Aridis Pharmaceuticals, Inc./In the news release, Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel, issued 27-Oct-2020 by Aridis Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the headline should read "Aridis Pharmaceuticals, Inc. toRHEA-AIneutral
10/27/20 5:30 AMNasdaq : ARDSAridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 PanelAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH CapitalRHEA-AIneutral
10/19/20 8:30 AMNasdaq : ARDSAridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 PatientsAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the development of a highly neutralizingRHEA-AIpositive
10/14/20 5:30 AMNasdaq : ARDSAridis Pharmaceuticals Announces $8.5 Million Registered Direct OfferingAridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into aRHEA-AIneutral
09/08/20 5:30 AMNasdaq : ARDSAridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the US Food andRHEA-AIneutral
09/04/20 1:32 PMNasdaq : ARDSAridis Pharmaceuticals to Present at Upcoming Investor ConferencesAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong, Ph.D., Chief ExecutiveRHEA-AIneutral
08/11/20 4:05 PMNasdaq : ARDSAridis Pharmaceuticals Announces Second Quarter 2020 ResultsAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the secondRHEA-AIneutral
06/26/20 5:30 AMNasdaq : ARDSAridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...RHEA-AIneutral
